Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionDnB Asset Management AS
Latest Disclosed Ownership31,427 shares
Latest Disclosed Value $ 10,398,251
DnB Asset Management AS reports 2.34% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - DnB Asset Management AS filed a 13F-HR form disclosing ownership of 31,427 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $8,978,694 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 30,707 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 2.34% during the quarter. The current value of the position is $8,186,734 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 31,427 720 2.34 10,398 -14.84 0.0371
2026-02-05 2025-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 30,707 -3,561 -10.39 12,211 -21.86 0.0426
2025-11-12 2025-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 34,268 6,805 24.78 15,626 74.49 0.0584
2025-08-12 2025-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 27,463 166 0.61 8,955 21.51 0.0371
2025-05-15 2025-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 27,297 564 2.11 7,371 17.17 0.0340
2025-02-12 2024-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 26,733 1,335 5.26 6,291 -9.95 0.0272
2024-11-12 2024-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 25,398 -617 -2.37 6,985 10.50 0.0315
2024-07-05 2024-06-30 13F Alnylam Pharmaceuticals common 02043Q107 26,015 1,022 4.09 6,322 69.24 0.0302
2024-04-12 2024-03-31 13F Alnylam Pharmaceuticals common 02043Q107 24,993 -21,231 -45.93 3,735 -57.78 0.0195
2024-01-04 2023-12-31 13F Alnylam Pharmaceuticals common 02043Q107 46,224 -4,988 -9.74 8,848 -2.45 0.0459
2023-10-13 2023-09-30 13F Alnylam Pharmaceuticals common 02043Q107 51,212 25,898 102.31 9,070 88.62 0.0542
2023-07-10 2023-06-30 13F/A-1 Alnylam Pharmaceuticals common 02043Q107 25,314 1,996 8.56 4,808 2.93 0.0276
2023-07-06 2023-06-30 13F Alnylam Pharmaceuticals common 02043Q107 25,314 1,996 4,808 0.0283
2023-04-20 2023-03-31 13F Alnylam Pharmaceuticals common 02043Q107 23,318 1,121 5.05 4,671 -11.45 0.0296
2023-01-12 2022-12-31 13F Alnylam Pharmaceuticals common 02043Q107 22,197 1,214 5.79 5,275 25.63 0.0372
2022-10-11 2022-09-30 13F Alnylam Pharmaceuticals common 02043Q107 20,983 -244 -1.15 4,200 35.67 0.0324
2022-07-08 2022-06-30 13F Alnylam Pharmaceuticals common 02043Q107 21,227 -128 -0.60 3,096 -11.24 0.0218
2022-04-08 2022-03-31 13F Alnylam Pharmaceuticals common 02043Q107 21,355 1,868 9.59 3,487 5.54 0.0207
2022-01-12 2021-12-31 13F Alnylam Pharmaceuticals common 02043Q107 19,487 1,670 9.37 3,305 -1.78 0.0194
2021-10-15 2021-09-30 13F Alnylam Pharmaceuticals common 02043Q107 17,817 -108 -0.60 3,364 10.73 0.0218
2021-07-06 2021-06-30 13F Alnylam Pharmaceuticals common 02043Q107 17,925 -5,461 -23.35 3,039 -7.97 0.0201
2021-04-15 2021-03-31 13F Alnylam Pharmaceuticals common 02043Q107 23,386 7,629 48.42 3,302 61.26 0.0241
2021-01-19 2020-12-31 13F Alnylam Pharmaceuticals common 02043Q107 15,757 2,322 17.28 2,048 4.65 0.0179
2020-10-14 2020-09-30 13F Alnylam Pharmaceuticals common 02043Q107 13,435 -78 -0.58 1,956 -2.25 0.0208
2020-07-08 2020-06-30 13F Alnylam Pharmaceuticals common 02043Q107 13,513 2,938 27.78 2,001 73.85 0.0235
2020-04-17 2020-03-31 13F Alnylam Pharmaceuticals common 02043Q107 10,575 -1,889 -15.16 1,151 -19.79 0.0169
2020-01-13 2019-12-31 13F Alnylam Pharmaceuticals common 02043Q107 12,464 1,109 9.77 1,435 57.17 0.0141
2019-10-16 2019-09-30 13F Alnylam Pharmaceuticals common 02043Q107 11,355 11,355 913 0.0103
2019-04-11 2019-03-31 13F Alnylam Pharmaceuticals common 02043Q107 0 -10,261 -100.00 0 -100.00
2019-01-15 2018-12-31 13F Alnylam Pharmaceuticals common 02043Q107 10,261 48 0.47 748 -16.24 0.0097
2018-10-10 2018-09-30 13F Alnylam Pharmaceuticals common 02043Q107 10,213 10,213 894 0.0100
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.